Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Showing posts with label Connecticut. Show all posts
Showing posts with label Connecticut. Show all posts

Saturday, May 16, 2015

State Moves To Make Costly Hepatitis C Drugs More Accessible To Medicaid Patients

HARTFORD — Connecticut is poised to make a new class of costly hepatitis C drugs more accessible to the state's poorest patients.

The state Department of Social Services will classify Sovaldi, Harvoni and Viekira Pak as preferred drugs in its Medicaid program, which means they will be "readily available to our clients,'' said department spokesman David Dearborn.

The department is also simplifying its prior authorization process, which had been criticized by advocates for hepatitis C patients as a tactic designed to limit access to the expensive but highly effective treatments.

Read more...

Thursday, March 19, 2015

Advocates Urge Easier Access To Expensive Drug For Medicaid Patients

Advocates for those living with Hepatitis C are urging the state Department of Social Services to ease new criteria patients must meet in order to have an expensive medication covered by Medicaid.

DSS has issued a bulletin to medical care providers, notifying them that patients with Hepatitis C who are enrolled in HUSKY A, HUSKY C or HUSKY D — parts of the state’s Medicaid program — must have “prior authorization” in order for prescriptions for the medication Sovaldi to be covered.

Prior authorization typically is required by insurers when they want to make sure certain prescription drugs are appropriately used. In essence, it requires enrollees to meet a higher threshold of criteria before insurers will agree to cover the medication’s expense.

Read more....